1 ve not recently been systematically assessed
despite advances in antiretroviral treatment (ART) poten
2 Despite advances in antiviral chemotherapy, herpes simpl
3 However,
despite advances in AON chemistry and design, systemic u
4 Despite advances in available immunosuppressive treatmen
5 Despite advances in betaIV-spectrin research in the nerv
6 Despite advances in cancer treatment over the past few d
7 Despite advances in cardiac arrest treatment, high morta
8 ival following sudden cardiac arrest is poor
despite advances in cardiopulmonary resuscitation and th
9 Despite advances in care, mortality and morbidity remain
10 Despite advances in care, the mortality rate in patients
11 by cumulative toxicity and limited efficacy
despite advances in chemotherapeutic and radiotherapeuti
12 Despite advances in chemotherapy and vaccine development
13 Purpose
Despite advances in childhood cancer care, some patients
14 Despite advances in childhood pneumonia management, it r
15 Despite advances in clinical imaging, detection and quan
16 Despite advances in clinical management, 5-year survival
17 Despite advances in clinical management, there are curre
18 Despite advances in clinical therapy, metastasis remains
19 Despite advances in combination chemotherapy, the overal
20 ients present with advanced disease in which
despite advances in combined modality therapy the outcom
21 Despite advances in complex wound management, appropriat
22 Despite advances in defining the critical molecular dete
23 Despite advances in detection and cytotoxic therapies, a
24 Despite advances in detection, comprehensive clinical, p
25 Despite advances in developing novel treatment modalitie
26 Despite advances in device design, there remains an appa
27 Despite advances in diagnosis and the use of different t
28 Despite advances in diagnosis and therapy, esophageal ad
29 onary embolism confers a high mortality rate
despite advances in diagnosis and therapy.
30 Despite advances in diagnosis and treatment, prostate ca
31 Despite advances in diagnosis and treatment, survival ra
32 Despite advances in diagnostic techniques, it remains di
33 Despite advances in diagnostics, less than 5% of patient
34 Despite advances in DNA sequencing technology, assembly
35 Despite advances in endovascular drug delivery, there is
36 Despite advances in formation of highly enantioenriched
37 Despite advances in genetic mapping of quantitative trai
38 reatment algorithms have been rewritten and,
despite advances in hematopoietic stem cell transplantat
39 Despite advances in high-throughput detection, the inert
40 Despite advances in high-throughput methods for discover
41 Despite advances in high-throughput sequencing, marine m
42 Despite advances in hospital management in recent years,
43 Despite advances in human immunodeficiency virus (HIV) t
44 Despite advances in hydrogen atom transfer (HAT) catalys
45 However,
despite advances in identifying and characterizing CD133
46 Despite advances in identifying deafness genes, determin
47 ese soft-tissue lesions remains problematic,
despite advances in imaging.
48 uences allograft function over the long term
despite advances in immunosuppression therapy.
49 Despite advances in immunosuppression, antibody-mediated
50 Despite advances in immunosuppressive therapies, the rat
51 Despite advances in interventional techniques, diabetes
52 ) and other rheumatic diseases remains poor,
despite advances in knowledge with regard to their patho
53 Despite advances in laboratory molecular-based detection
54 Despite advances in lithotripsy technology, bleeding con
55 Despite advances in live animal imaging with PAT, there
56 Despite advances in macromolecular structure determinati
57 nd mortality in critically ill patients, and
despite advances in management, mortality remains high.
58 Despite advances in management, VGF remains one of the l
59 Despite advances in mechanical ventilation for ARDS, man
60 is a major cause of morbidity and mortality
despite advances in medical and device therapy.
61 sease (CD) patients is still currently valid
despite advances in medical and surgical treatments.
62 Despite advances in medical care, preterm birth and its
63 Despite advances in medical device fabrication and antim
64 Despite advances in medical management, the survival rat
65 Despite advances in medical therapies to help prevent th
66 Despite advances in medical therapy and percutaneous rev
67 Despite advances in medical therapy, congestive heart fa
68 Despite advances in medical therapy, HF continues to be
69 Despite advances in medical therapy, liver replacement c
70 c death remains a leading cause of mortality
despite advances in medical treatment for the prevention
71 Despite advances in medical, percutaneous, and surgical
72 he general population is still not confirmed
despite advances in medicine.
73 Despite advances in metabolite profiling, a full picture
74 Despite advances in modeling the risks of this toxic and
75 Despite advances in modern medicine, there are few optio
76 Despite advances in molecular diagnostics, the ability t
77 Despite advances in monitoring spatiotemporal expression
78 PURPOSE OF REVIEW:
Despite advances in multimodality therapy, the overall 5
79 Despite advances in multimodality therapy, the prognosis
80 However,
despite advances in nanowire synthesis, progress towards
81 Despite advances in neurobiological understanding of res
82 Despite advances in neuroimaging, there are currently li
83 Despite advances in next-generation sequencing (NGS) and
84 Despite advances in obstetrics and neonatology, the rate
85 Despite advances in oncology drug development, most comm
86 Despite advances in operative technique and perioperativ
87 horacic and thoracoabdominal aortic aneurysm
despite advances in operative technique.
88 Despite advances in organometallic cross-coupling of alk
89 Despite advances in our understanding and management of
90 Despite advances in our understanding of E7, reagents th
91 Yet
despite advances in our understanding of evolution, what
92 Despite advances in our understanding of GRP78 actions,
93 Despite advances in our understanding of mechano- and th
94 causes of morbidity and mortality worldwide
despite advances in our understanding of pathophysiology
95 Yet,
despite advances in our understanding of productivity at
96 Despite advances in our understanding of the mechanisms
97 itherto defied all attempts at reproduction,
despite advances in our understanding of the molecular m
98 se has undergone little change in many years
despite advances in our understanding of the pathogenesi
99 Despite advances in our understanding of the ways in whi
100 Despite advances in perioperative care of the recipient,
101 y suffer substantial morbidity and mortality
despite advances in perioperative care, whereas patients
102 Despite advances in pharmacological treatments aimed at
103 Despite advances in pharmacotherapy and stents, reinfarc
104 Despite advances in physicochemical remediation technolo
105 Despite advances in prevention and treatment, sexually t
106 Despite advances in preventive, diagnostic, and therapeu
107 Despite advances in promoting axonal regeneration after
108 Despite advances in prophylaxis and treatment, cytomegal
109 Despite advances in quantitative biology, full parameter
110 Despite advances in recent methods conducted on large da
111 Despite advances in renal replacement therapy, the morta
112 Despite advances in reperfusion therapy, acute coronary
113 Despite advances in resolution accompanying the developm
114 Despite advances in resting state functional magnetic re
115 out-of-hospital cardiac arrest remains high
despite advances in resuscitation and early revasculariz
116 Despite advances in resuscitation care in recent years,
117 Despite advances in resuscitation methods, survival afte
118 Despite advances in resuscitation science, basic life su
119 Despite advances in resuscitation science, basic life su
120 Despite advances in rheumatoid arthritis (RA) treatment,
121 n rheumatoid arthritis has remained stagnant
despite advances in rheumatoid arthritis and heart failu
122 Despite advances in ribosome structural biology, identif
123 Despite advances in search technology, users prefer retr
124 Despite advances in sequence-based microbial profiling a
125 Despite advances in sequencing technology, discovering r
126 f bacterial genomes remains labor-intensive,
despite advances in sequencing technology.
127 Despite advances in sequencing, the goal of obtaining a
128 te for the detection of obstructive CAD and,
despite advances in SPECT technology, remains superior.
129 ion (PCI) for ACS remains a clinical problem
despite advances in stent technology in both bare-metal
130 Despite advances in support and the development of novel
131 th unacceptably high morbidity and mortality
despite advances in supportive care measures and bacteri
132 Despite advances in supportive care, fulminant-phase inh
133 Despite advances in supportive therapy to prevent compli
134 Despite advances in surgery and radiation, most malignan
135 Despite advances in surgery, imaging, chemotherapy, and
136 Despite advances in surgery, radiation therapy, and chem
137 as not significantly changed in two decades,
despite advances in surgery, radiation, and chemotherapy
138 Despite advances in surgery, radiotherapy, and chemother
139 Despite advances in surgical and medical management of p
140 Despite advances in surgical and medical therapies, appr
141 Despite advances in surgical and percutaneous coronary r
142 Despite advances in surgical chemotherapeutic and radiot
143 male cancer-related morbidity and mortality,
despite advances in surgical management and innovations
144 f lost periodontium remains an elusive goal,
despite advances in surgical procedures and materials.
145 Despite advances in surgical technique and material, pos
146 Despite advances in surgical technique and multimodality
147 duodenal cancer mortality rates remain high
despite advances in surgical technique, perioperative ca
148 Despite advances in the chemical synthesis of alpha-syn
149 Despite advances in the curative treatment of acute myel
150 Despite advances in the diagnosis and management of idio
151 Despite advances in the diagnosis and treatment of Clost
152 Despite advances in the diagnosis and treatment of IR, n
153 Despite advances in the diagnosis and treatment of SAH,
154 Despite advances in the field of lung transplantation, t
155 Despite advances in the field, the development of precis
156 Despite advances in the gene annotation process, the fun
157 Despite advances in the gene-set enrichment analysis met
158 Despite advances in the identification of ASD risk genes
159 Despite advances in the identification of genomic and mo
160 Despite advances in the identification of lymphoid-restr
161 Despite advances in the identification of novel gene mut
162 Despite advances in the management of myeloablative allo
163 Despite advances in the management of non-small-cell lun
164 Despite advances in the management of osteosarcoma (OSA)
165 Despite advances in the management of rectal cancer, loc
166 Despite advances in the management of sepsis and acute r
167 Despite advances in the management of sickle cell diseas
168 Despite advances in the management of this disease, the
169 Despite advances in the methods for discovery of putativ
170 Despite advances in the miniaturization of solid-phase e
171 Despite advances in the molecular biology of cardiac myo
172 Despite advances in the molecular epidemiology of C. neo
173 Despite advances in the molecular genetics of these two
174 Despite advances in the molecular pathogenesis of gliobl
175 ldren and adolescents with rheumatic disease
despite advances in the pharmacological management of th
176 Despite advances in the prophylaxis and acute treatment
177 Despite advances in the sensitivity of silicon photonic
178 Despite advances in the study of molecular biology of ca
179 Despite advances in the therapeutic use of recombinant g
180 Despite advances in the treatment of asthma, optimizatio
181 Despite advances in the treatment of bipolar disorder, a
182 Despite advances in the treatment of HIV, HIV-infected p
183 Despite advances in the treatment of schizophrenia spect
184 Despite advances in the understanding of pathways regula
185 Despite advances in therapeutics, renal damage in partic
186 Despite advances in therapy for heart failure, improveme
187 Despite advances in therapy, many patients with systemic
188 Despite advances in therapy, morbidity and mortality fro
189 Despite advances in therapy, nearly 30% of children with
190 Despite advances in therapy, patients with a histologic
191 Despite advances in therapy, patients with a histologic
192 remains a substantial and increasing problem
despite advances in therapy.
193 Despite advances in this area, further research is neede
194 Despite advances in treatment and prognosis of non-small
195 g retinoblastoma with seeding is challenging
despite advances in treatment modalities.
196 Despite advances in treatment of both cardiovascular and
197 Despite advances in treatment of DKA, the pathogenesis o
198 Despite advances in treatment strategies for hepatitis C
199 Despite advances in treatment, including the introductio
200 Despite advances in treatment, mortality in acute myocar
201 Despite advances in treatment, there was little evidence
202 Despite advances in trimer design, the roots of Env trim
203 Despite advances in understanding how ATM signals cell c
204 Despite advances in understanding its immunopathogenesis
205 However,
despite advances in understanding murine Th17 differenti
206 Despite advances in understanding of ALS disease progres
207 Despite advances in understanding of the disease, it rem
208 Despite advances in understanding the cell biology of gl
209 major challenges in diagnosis and management
despite advances in understanding the epidemiology, micr
210 Despite advances in understanding the molecular basis of
211 stress have recently been demonstrated, but
despite advances in understanding the pathogenesis, ther
212 Despite advances in understanding the pathophysiology of
213 Despite advances in understanding the pathophysiology of
214 Despite advances in understanding the patterns and proce
215 Despite advances in understanding the role of histone de
216 ment in outcomes seen in more than 2 decades
despite advances in upfront therapy and improved surviva
217 Despite advances in urban ecology, we do not adequately
218 Despite advances in ventilatory management, FC remains a
219 Despite advances in X-ray information, the organization